千红制药：QHRD107已完成IIa期全部患者入组，正积极与CDE开展关键性临床沟通工作

Group 1 - The company Qianhong Pharmaceutical (002550.SZ) has completed Phase II clinical trials for its innovative drug QHRD106 and has submitted the relevant materials to the CDE for review, with plans to enter Phase III clinical trials upon approval [1] - QHRD107 has completed patient enrollment for Phase IIa and is actively engaging in critical clinical communication with the CDE to advance its clinical research [1] - The company encourages investors to pay attention to future announcements for specific progress updates [1]